Lumida
/TDOC
⌘K
Teladoc Health Inc

Teladoc Health Inc

TDOC
$6.10USD-2.56%-0.16 today

MARKET CAP

1.1B

P/E (TTM)

FWD P/E

DAY RANGE

$6 – $6

52W RANGE

$4
$10

AI Summary

Stalk
StalkMedium

TDOC is carving out a post-capitulation base after the mid-August flush, with supply exhaustion confirmed and oversold context supporting a mean-reversion setup. Medium-term bias is bullish, but short-term timing remains neutral as price consolidates around declining EMAs. We will stalk for pullback acceptance into the base range and EMAs before scaling in.

  • Integrated care revenue $394M, +0.7% YoY in Q2 2026
  • $774M cash enables strategic investments and scaling insurance
  • BetterHelp revenue declined 11.6% YoY to $213M
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2021FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$2.0B$2.4B$2.6B$2.6B$2.5B
YoY %+85.8%+18.4%+8.1%-1.3%-1.5%
P / Sales7.1x1.5x1.4x0.6x0.5x
EV / Sales7.5x2.0x1.7x0.9x0.8x
Gross Profit, Adj.$1.4B$1.7B$1.8B$1.8B$1.8B
YoY %+96.6%+20.3%+10.8%-1.3%-3.3%
Margin %68.0%69.1%70.8%70.8%69.5%
EV / Gross Profit11.0x2.9x2.5x1.3x1.1x
EBITDA, Adj.$-19.4M$28.7M$126.6M$164.8M$200.7M
YoY %+94.4%+248.0%+341.6%+30.2%+21.8%
Margin %-1.0%1.2%4.9%6.4%7.9%
EV / EBITDA-785.1x166.3x36.0x13.8x9.6x
EBIT$-265.6M$-13.7B$-248.6M$-1.0B$-263.0M
YoY %+47.5%-5039.9%+98.2%-310.7%+74.2%
Margin %-13.1%-567.3%-9.6%-39.7%-10.4%
EV / EBIT-57.2x-0.3x-18.3x-2.2x-7.3x
Net Income$-428.8M$-13.7B$-220.4M$-1.0B$-200.3M
YoY %+11.6%-3085.6%+98.4%-354.4%+80.0%
Net Margin-21.1%-567.5%-8.5%-39.0%-7.9%
EPS (GAAP)-$2.73-$84.60-$1.34-$5.87-$1.14
YoY %+49.1%-2998.9%+98.4%-338.1%+80.6%